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Abstract Microtubule-associated protein tau is abnormally hy-
perphosphorylated, glycosylated, and aggregated in a¡ected
neurons in the brains of individuals with Alzheimer’s disease
(AD). We recently found that the glycosylation might precede
hyperphosphorylation of tau in AD. In this study, we investi-
gated the e¡ect of glycosylation on phosphorylation of tau cat-
alyzed by cyclin-dependent kinase 5 (cdk5) and glycogen syn-
thase kinase-3L (GSK-3L). The phosphorylation of the longest
isoform of recombinant human brain tau, tau441, at various sites
was detected by Western blots and by radioimmuno-dot-blot
assay with phosphorylation-dependent and site-speci¢c tau anti-
bodies. We found that cdk5 phosphorylated tau441 at Thr-181,
Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-
231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-
400, Thr-403, Ser-409, Ser-413, or Ser-422. GSK-3L phosphor-
ylated all the cdk5-catalyzed sites above except Ser-235. Degly-
cosylation by glycosidases depressed the subsequent phosphory-
lation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202,
Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3L
at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at
Ser-199, Thr-212, Thr-231, or Ser-396. These data suggest that
aberrant glycosylation of tau in AD might be involved in neuro-
¢brillary degeneration by promoting abnormal hyperphosphor-
ylation by cdk5 and GSK-3L.
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1. Introduction
The formation of neuro¢brillary tangles (NFTs) in the brain
is one of the neuropathological hallmarks of Alzheimer’s
disease (AD) and the number of NFTs correlates with the
degree of dementia. Ultrastructurally, NFTs are composed of
bundles of paired helical ¢laments (PHFs), the major protein
subunit of which is microtubule-associated protein tau in
an abnormally hyperphosphorylated form [1^4]. Hyperphos-
phorylated tau lacks normal tau’s activity to bind to micro-
tubules and to stimulate their assembly [5^8]. Instead, it
sequesters normal tau and other microtubule-associated pro-
teins and disassembles microtubules [6,9^11]. The abnormal
hyperphosphorylation of tau also promotes its self-assembly
into PHFs [11]. Thus, elucidating the molecular mechanism
by which tau becomes abnormally hyperphosphorylated is
critical to understanding the pathogenesis of AD.
Tau can be phosphorylated in vitro by several protein ki-
nases. Among them, cyclin-dependent kinase 5 (cdk5) and
glycogen synthase kinase-3L (GSK-3L) are believed to be the
most important kinase candidates that regulate tau phosphor-
ylation in the brain (for review, see [12^14]). Two kinases
initially puri¢ed from microtubule preparation and identi¢ed
as tau protein kinase I and II are actually GSK-3L and cdk5,
respectively [15,16]. These two kinases phosphorylate tau at
many phosphorylation sites seen in PHFs [17^29]. Phosphor-
ylation of tau with these kinases inhibits its ability to bind to
microtubules and to promote their assembly, and facilitates its
polymerization into PHFs [29^34]. However, biochemical
studies demonstrated no up-regulation of these kinases in
AD brain [35^38]. Thus, one of the possibilities is that abnor-
mal hyperphosphorylation might be the result of some mod-
i¢cation of tau that converts it into a better substrate for
phosphorylation.
In addition to being abnormally hyperphosphorylated, tau
in AD brain is also aberrantly glycosylated with oligosaccha-
rides [39]. This discovery was further supported and con¢rmed
by strong staining of PHF tangles with lectins speci¢c to gly-
coproteins on tissue sections of AD brain [40] and by analyses
of the structure and sugar composition of the oligosaccharides
hydrolyzed from the abnormally hyperphosphorylated tau pu-
ri¢ed from AD brains [41,42]. Our recent studies suggested
that the aberrant glycosylation might precede the abnormal
hyperphosphorylation and facilitate the phosphorylation of
tau catalyzed by cyclic AMP-dependent protein kinase
[42,43]. These ¢ndings urged us to investigate whether the
aberrant glycosylation a¡ects the subsequent phosphorylation
of tau by cdk5 and GSK-3L, which are among the kinases
most strongly implicated in the abnormal hyperphosphoryla-
tion of tau in AD brain.
In this study, we employed phosphorylation-dependent and
site-speci¢c tau antibodies to detect the phosphorylation of
human tau at each speci¢c site. We found that cdk5 phos-
phorylated the largest isoform of recombinant human tau,
tau441, at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-
214, Thr-217, Thr-231, Ser-235, Ser-396, and Thr-404. GSK-
3L phosphorylated all the cdk5-catalyzed sites above except
Ser-235. The aberrant glycosylation facilitated the subsequent
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phosphorylation catalyzed by either cdk5 or GSK-3L at sev-
eral abnormal hyperphosphorylation sites in a site-speci¢c
manner.
2. Materials and methods
2.1. Materials
The tau polyclonal antibodies 92e, R111e, R134d, and R145 were
raised in rabbits, as reported previously [44^46]. Phosphorylation-de-
pendent and site-speci¢c tau antibodies pT181, pS199, pS202, pT205,
pT212, pS214, pT217, pT231, pS235, pS262, pS396, pS400, pT403, pS404,
pS409, and pS413 were purchased from Biosource International (Cama-
rillo, CA, USA). 125I-labeled anti-mouse and anti-rabbit whole anti-
bodies were from Amersham Pharmacia Biotech (Piscataway, NJ,
USA). Alkaline phosphatase-conjugated goat anti-mouse IgG and
anti-rabbit IgG were from Sigma (St. Louis, MO, USA). The total
glycan detection kit, peptide-N-glycosidase F (PNGase F), O-glycosi-
dase, and sialidase were purchased from Boehringer Mannheim (In-
dianapolis, IN, USA). GSK-3L was from Calbiochem (San Diego,
CA, USA). Recombinant cdk5 and p25 (an activator of cdk5) were
expressed, puri¢ed, and reconstituted into an active holoenzyme, as
described previously [47]. [Q-32P]adenosine triphosphate (ATP) was
bought from ICN Biomedicals (Costa Mesa, CA, USA).
The autopsied human brain tissue used for this study was obtained
within 6 h postmortem and was stored at 375‡C until used. Two AD
brains were included in this study. They were both histopathologically
con¢rmed and were supplied by the Brain Tissue Resource Center of
McLean Hospital (Belmont, MA, USA).
2.2. Preparation of tau proteins
The largest isoform of recombinant human tau, tau441, was ex-
pressed and puri¢ed from Escherichia coli as described previously
[11]. The cytosolic non-hyperphosphorylated tau (AD-tau) was puri-
¢ed from AD brains as described previously [48]. Brie£y, 5% homog-
enate was prepared from the cerebral cortex of AD cases and centri-
fuged at 27 000Ug for 30 min to remove cellular debris and NFTs.
The supernatant was centrifuged again at 200 000Ug for 45 min, and
the second pellet was extracted with 8 M urea at room temperature
(22‡C) for 60 min. The extract was centrifuged at 334 000Ug for 45
min at 22‡C, and the resultant supernatant was dialyzed and subjected
to phosphocellulose (PII, Whatman) cation-exchange chromatogra-
phy. AD-tau was eluted by 0.31^0.8 M NaCl. The concentration of
tau in the preparations was determined by radioimmuno-dot-blot as-
say [42,43,49] using a mixture of three polyclonal tau antibodies (92e,
R111e and R134d) as a primary antibody, and recombinant tau441 as
a standard.
2.3. Enzymatic deglycosylation of tau
AD-tau (400 Wg) was diluted to a total volume of 4.0 ml with a
deglycosylation bu¡er containing 20 mM sodium phosphate, pH 7.2,
20 mM ethylenediamine tetraacetic acid (EDTA), and 10 mM L-mer-
captoethanol, and was heated in a 95‡C water bath for 20 min. After
being sonicated in a bath sonicator for 20 min, the sample was divided
into two equal parts of 2.0 ml each. Into one part, PNGase F (6 U/
ml), O-glycosidase (7.5 mU/ml), sialidase (50 mU/ml), and a cocktail
of protease inhibitors were added. Into the other half, deionized water
was added instead. The two tubes were then incubated at 37‡C over-
night, followed by heating at 95‡C and bath sonication for 10 min
each. The samples were then centrifuged at 14 000Ug for 10 min to
remove the denatured enzymes. The heat-stable tau in the supernatant
was concentrated from 2.0 ml to approximately 400 Wl by a speed
vacuum concentrator, followed by dialysis against 40 mM HEPES,
pH 7.5, 10 mM L-mercaptoethanol, and 10 mM MgCl2. The degly-
cosylated and control-treated AD-tau were stored at 320‡C until
used. The tau concentration of the samples was determined by a
radioimmuno-dot-blot assay [49,43], and the success of the deglyco-
sylation was examined by using the total glycan detection kit (Roche
Molecular Biochemicals).
2.4. Phosphorylation of tau
The in vitro phosphorylation was carried out by incubating tau441
(0.2 mg/ml) at 30‡C in a phosphorylation reaction mixture. For cdk5-
catalyzed phosphorylation, the reaction mixture contained 40 mM
HEPES (pH 7.5), 10 mM L-mercaptoethanol, 10 mM MgCl2, 0.2
mM [Q-32P]ATP, 6.4 Wg/ml cdk5, and protease inhibitors (2 Wg/ml
aprotinin, 2 Wg/ml pepstatin, 5 Wg/ml leupeptin, and 1 mM phenyl-
methylsulfonyl £uoride (PMSF)). For GSK-3L-catalyzed phosphory-
lation, the mixture contained 40 mM HEPES (pH 7.5), 10 mM
MgCl2, 0.5 mM dithiothreitol (DTT), 2 mM ethyleneglycol-bis-
(L-aminoethylether)-N,N,NP,NP-tetraacetic acid (EGTA), 0.2 mM [Q-
32P]ATP, 200 U/ml GSK-3L, and protease inhibitors. After incubation
for various periods of time, the reaction was stopped, the 32P-labeled
tau was separated from free [Q-32P]ATP by paper chromatography,
and the radioactivity of tau was determined by Cerenkov counting,
as described previously [50]. For detecting site-speci¢c phosphoryla-
tion, the phosphorylation reaction was carried out with non-radio-
active ATP, and the reaction was stopped by adding 1/3 volume of
four-fold concentrated sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE) sample bu¡er (240 mM Tris^HCl, pH
6.8, 8% SDS, 20% L-mercaptoethanol, 40% glycerol, and 0.08% bro-
mophenol blue), followed by heating in boiling water for 5 min. The
phosphorylation of tau at each speci¢c site was detected by Western
blots with various phosphorylation-dependent and site-speci¢c tau
antibodies (at a dilution of 1:1000), as described previously [51]. A
phosphorylation-independent tau antibody, R134d (1:5000), was also
used to detect total tau.
The phosphorylation of AD-tau with and without prior deglycosy-
lation was carried out using the same conditions as described above
for tau441, except that 0.4 mg/ml of AD-tau was used. The reaction
was terminated by heating in a boiling water bath for 5 min. After the
mixture was cooled down, the phosphorylation of AD-tau at each
speci¢c site was measured by using a radioimmuno-dot-blot assay,
as described [43].
3. Results and discussion
Several studies have reported in vitro phosphorylation of
tau by cdk5 and GSK-3L at various sites as detected with
di¡erent methods [17^29]. To study the e¡ect of glycosylation
on site-speci¢c phosphorylation of tau catalyzed by cdk5 and
GSK-3L, we ¢rst needed to ensure that the phosphorylation at
each of these sites could be detected and quantitatively mea-
sured under the conditions used. For this purpose, we phos-
phorylated tau441 in vitro with these two kinases. We found
that under the phosphorylation conditions used, cdk5 and
GSK-3L each phosphorylated tau to a stoichiometry of ap-
proximately 1.5 mol Pi/mol tau during 3 h (Fig. 1A, B). These
results are consistent with those reported previously
[26,27,52]. Since tau is phosphorylated at multiple sites by
either of these kinases, the stoichiometric phosphorylation
of tau shown in Fig. 1A, B should be a sum of sub-stoichio-
metric phosphorylation of tau at these sites. We further ex-
amined the phosphorylation of tau at each speci¢c site by
Western blots developed with various phosphorylation-depen-
dent and site-speci¢c antibodies. None of these antibodies
stained tau441 prior to the in vitro phosphorylation (Fig. 1C,
D, left lanes), although the presence of tau was con¢rmed
with the phosphorylation-independent antibody R134d. After
incubation with cdk5 or GSK-3L for 3 h (right lanes), tau was
recognized by several of these antibodies, indicating phos-
phorylation at the sites recognized by these antibodies. On
the basis of immunostaining of tau with these antibodies after
incubation with cdk5 or GSK-3L, we summarized the phos-
phorylation sites of tau with these kinases and compared our
results with those reported in the literature (Table 1). By
means of amino acid sequencing, mass spectrometry, and
Western blots developed with phosphorylation-dependent
antibodies, up to 29 phosphorylation sites of PHF-tau have
been identi¢ed to date (see Table 1). Many of these tau sites
can be phosphorylated in vitro with cdk5 or GSK-3L. Regard-
ing the site-speci¢c phosphorylation with cdk5 and GSK-3L,
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our results were consistent with those reported previously,
except that Ser-235, Ser-262, and Ser-400 were not phosphor-
ylated by GSK-3L under our conditions. The in vitro phos-
phorylation of tau at these sites by GSK-3L can only be ob-
tained in the presence of heparin or after prephosphorylation
of tau by cyclic AMP-dependent protein kinase [21,23,26,27].
We did not prephosphorylate tau with cyclic AMP-dependent
protein kinase or include heparin in the phosphorylation re-
action mixture.
Fig. 1C indicates very strong immunoreactivity of tau phos-
phorylated by cdk5 with antibodies against phosphorylated
Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, and Ser-404.
Hence, we developed a radioimmuno-dot-blot assay with
these six antibodies to measure the cdk5-catalyzed phosphor-
ylation of tau at each of the six phosphorylation sites. This
assay was used to study the e¡ect of aberrant glycosylation on
the cdk5-catalyzed phosphorylation at each of these sites. For
this purpose, we used AD-tau puri¢ed from AD brain as a
substrate because it is aberrantly glycosylated but not hyper-
phosphorylated [42]. We ¢rst removed glycans from AD-tau
by treatment with glycosidases. The deglycosylated and con-
trol-treated AD-tau were then used as substrates in parallel
for in vitro phosphorylation with cdk5. We found that the
deglycosylated AD-tau was phosphorylated by cdk5 at Thr-
Fig. 1. Cdk5 and GSK-3L phosphorylate tau at multiple sites. The largest isoform of recombinant human brain tau, tau441, was incubated at
30‡C in a phosphorylation reaction mixture containing [Q-32P]ATP and either cdk5/p25 (A) or GSK-3L (B). After various periods of incubation,
the reaction was stopped, the 32P incorporated into tau was separated from the free [Q-32P]ATP by paper chromatography, and the radioactivity
was determined by Cerenkov counting. C and D: tau441 phosphorylated with cdk5/p25 (C) or GSK-3L (D) for 3 h, as described above, except
that the [Q-32P]ATP was replaced with non-radioactive ATP. The phosphorylation of tau at each speci¢c site after incubation with (right lanes)
or without (left lanes) the kinase was detected by Western blots (375 ng tau/lane) developed with phosphorylation-dependent and site-speci¢c
tau antibodies. These antibodies include pT181, pS199, pS202, pT205, pT212, pS214, pT217, pT231, pS235, pS262, pS396, pS400, pT403, pS404, pS409,
pS413, and R145d for pS422. A phosphorylation-independent antibody, R134d, was employed for detecting both phosphorylated and unphos-
phorylated tau. Cdk5 phosphorylated tau441 at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and
Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422; and GSK-3L phosphorylated all the above cdk5-catalyzed sites ex-
cept Ser-235. The phosphorylation by either kinase also produced an up-shift of gel mobility of tau441. Not shown here are positive stainings
of PHF-tau with antibodies pS262, pS400, pT403, pS409, pS413, and R145.
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181, Ser-199, Ser-202, Thr-205 and Ser-404 at a slower rate
and to a smaller extent than the control-treated AD-tau (Fig.
2). However, the deglycosylation did not a¡ect the cdk5-cata-
lyzed phosphorylation of tau at Thr-212. These results suggest
that the aberrant glycosylation may facilitate phosphorylation
of tau by cdk5 at selective sites.
The e¡ect of glycosylation on the site-speci¢c phosphoryla-
tion catalyzed by GSK-3L was similarly studied. We found
that the deglycosylated AD-tau was phosphorylated by
GSK-3L at Thr-181, Ser-202, Thr-205, Thr-217, and Ser-404
at a slower rate and to a smaller extent than the control-
treated AD-tau (Fig. 3), whereas the phosphorylation of
AD-tau at Ser-199, Thr-212, Thr-231, or Ser-396 by GSK-
3L was not signi¢cantly a¡ected by deglycosylation. These
data suggest that the aberrant glycosylation di¡erentially
modulates GSK-3L-catalyzed phosphorylation in a site-specif-
ic manner, facilitating phosphorylation of tau at some of the
sites.
Tau in AD brain is mainly N-glycosylated via N-linkage of
the oligosaccharides at asparagine residues [39,41,42]. Unlike
O-linked glycosylation that occupies the hydroxyl groups of
serine/threonine residues and makes them unavailable for sub-
sequent phosphorylation, the aberrant N-glycosylation of tau
Fig. 3. E¡ect of deglycosylation on phosphorylation of tau with GSK-3L. The deglycosylated (b) and control-treated AD-tau (a) was incuba-
ted with GSK-3L at 30‡C for various periods. Then, the phosphorylation of tau at speci¢c sites was determined by radioimmuno-dot-blot as-
say, as in Fig. 2. The error bar represents the S.D. of the three individual experiments. The deglycosylation depressed phosphorylation of AD-
tau with GSK-3L at Thr-181, Ser-202, Thr-205, Thr-217, and Ser-404, but had no signi¢cant e¡ect on the phosphorylation at Ser-199, Thr-212,
Thr-231, and Ser-396.
Fig. 2. E¡ect of deglycosylation on phosphorylation of tau with
cdk5. AD-tau was deglycosylated by PNGase F, O-glycosidase, and
sialidase overnight at 37‡C. The deglycosylated (b) and control-
treated AD-tau (a) was incubated with recombinant cdk5/p25 at
30‡C for various periods. The phosphorylation of tau at each site
was detected by a radioimmuno-dot-blot assay using pT181, pS199,
pS202, pT205, pT212, and pS404 as primary antibodies, and 125I-la-
beled anti-rabbit whole antibody as secondary antibody. The error
bar represents the S.D. of the three individual experiments. Com-
pared with the control-treated AD-tau, the deglycosylated AD-tau
was phosphorylated by cdk5 at a slower rate and to a smaller ex-
tent at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at
Thr-212.
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in AD appears to make it a more favorable substrate for
phosphorylation by cdk5 and GSK-3L at several but not all
sites. Interestingly, the aberrant glycosylation did not inhibit
the phosphorylation of tau by cdk5 or GSK-3L at any of the
sites examined in the present study.
Because abnormal hyperphosphorylation of tau is pivotal
to neuro¢brillary degeneration in AD and other tauopathies,
elucidating factors that modulate tau phosphorylation is sig-
ni¢cant. Our ¢nding that aberrant glycosylation positively
modulates phosphorylation of tau by cdk5, GSK-3L (this
study) and cyclic AMP-dependent protein kinase [43] explains
the possible role of aberrant glycosylation in neuro¢brillary
degeneration. The inhibition of aberrant glycosylation of tau
might be a promising target to inhibit the abnormal hyper-
phosphorylation of tau and, consequently, the neuro¢brillary
degeneration.
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